Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Growth (Status and Outlook) 2025-2031

January 2025 | 92 pages | ID: G02AD491A88EN
LP Information

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

The global Amyotrophic Lateral Sclerosis (ALS) Treatment market size is predicted to grow from US$ 343 million in 2025 to US$ 556 million in 2031; it is expected to grow at a CAGR of 8.4% from 2025 to 2031.

Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.

The cause is not known in 90% to 95% of cases. The remaining 5–10% of cases are inherited from a person's parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.

GlobalAmyotrophic Lateral Sclerosis (ALS) Treatment key players include Mitsubishi Tanabe Pharma, Sanofi, etc. Global top two manufacturers hold a share over 80%.

North America is the largest market, with a share about 60%, followed by Japan, and Europe, both have a share over 20 percent.

In terms of product, Edaravone (Radicava) is the largest segment, with a share over 75%. And in terms of application, the largest application is Hospital, followed by Drugs Store, etc.

LPI (LP Information)' newest research report, the “Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Forecast” looks at past sales and reviews total world Amyotrophic Lateral Sclerosis (ALS) Treatment sales in 2024, providing a comprehensive analysis by region and market sector of projected Amyotrophic Lateral Sclerosis (ALS) Treatment sales for 2025 through 2031. With Amyotrophic Lateral Sclerosis (ALS) Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Amyotrophic Lateral Sclerosis (ALS) Treatment industry.

This Insight Report provides a comprehensive analysis of the global Amyotrophic Lateral Sclerosis (ALS) Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Amyotrophic Lateral Sclerosis (ALS) Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Amyotrophic Lateral Sclerosis (ALS) Treatment market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Amyotrophic Lateral Sclerosis (ALS) Treatment and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Amyotrophic Lateral Sclerosis (ALS) Treatment.

This report presents a comprehensive overview, market shares, and growth opportunities of Amyotrophic Lateral Sclerosis (ALS) Treatment market by product type, application, key players and key regions and countries.

Segmentation by Type:

• Riluzole
• Edaravone (Radicava)
• Other

Segmentation by Application:

• Hospital
• Drugs Store
• Other

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

• Mitsubishi Tanabe Pharma
• Sanofi
• Mylan Pharma
• Apotex
• Glemark Generics
• Covis Pharma
• Sun Pharma
• Lunan Pharma

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2020-2031)
  2.1.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size CAGR by Region (2020 VS 2024 VS 2031)
  2.1.3 World Current & Future Analysis for Amyotrophic Lateral Sclerosis (ALS) Treatment by Country/Region (2020, 2024 & 2031)
2.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Segment by Type
  2.2.1 Riluzole
  2.2.2 Edaravone (Radicava)
  2.2.3 Other
2.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type
  2.3.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size CAGR by Type (2020 VS 2024 VS 2031)
  2.3.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Market Share by Type (2020-2025)
2.4 Amyotrophic Lateral Sclerosis (ALS) Treatment Segment by Application
  2.4.1 Hospital
  2.4.2 Drugs Store
  2.4.3 Other
2.5 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application
  2.5.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size CAGR by Application (2020 VS 2024 VS 2031)
  2.5.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Market Share by Application (2020-2025)

3 AMYOTROPHIC LATERAL SCLEROSIS (ALS) TREATMENT MARKET SIZE BY PLAYER

3.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Market Share by Player
  3.1.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Player (2020-2025)
  3.1.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Player (2020-2025)
3.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
  3.3.1 Competition Landscape Analysis
  3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion

4 AMYOTROPHIC LATERAL SCLEROSIS (ALS) TREATMENT BY REGION

4.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region (2020-2025)
4.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Annual Revenue by Country/Region (2020-2025)
4.3 Americas Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth (2020-2025)
4.4 APAC Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth (2020-2025)
4.5 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth (2020-2025)
4.6 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth (2020-2025)

5 AMERICAS

5.1 Americas Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2020-2025)
5.2 Americas Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2020-2025)
5.3 Americas Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region (2020-2025)
6.2 APAC Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2020-2025)
6.3 APAC Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia

7 EUROPE

7.1 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2020-2025)
7.2 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2020-2025)
7.3 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment by Region (2020-2025)
8.2 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2020-2025)
8.3 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 GLOBAL AMYOTROPHIC LATERAL SCLEROSIS (ALS) TREATMENT MARKET FORECAST

10.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Forecast by Region (2026-2031)
  10.1.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Forecast by Region (2026-2031)
  10.1.2 Americas Amyotrophic Lateral Sclerosis (ALS) Treatment Forecast
  10.1.3 APAC Amyotrophic Lateral Sclerosis (ALS) Treatment Forecast
  10.1.4 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Forecast
  10.1.5 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Forecast
10.2 Americas Amyotrophic Lateral Sclerosis (ALS) Treatment Forecast by Country (2026-2031)
  10.2.1 United States Market Amyotrophic Lateral Sclerosis (ALS) Treatment Forecast
  10.2.2 Canada Market Amyotrophic Lateral Sclerosis (ALS) Treatment Forecast
  10.2.3 Mexico Market Amyotrophic Lateral Sclerosis (ALS) Treatment Forecast
  10.2.4 Brazil Market Amyotrophic Lateral Sclerosis (ALS) Treatment Forecast
10.3 APAC Amyotrophic Lateral Sclerosis (ALS) Treatment Forecast by Region (2026-2031)
  10.3.1 China Amyotrophic Lateral Sclerosis (ALS) Treatment Market Forecast
  10.3.2 Japan Market Amyotrophic Lateral Sclerosis (ALS) Treatment Forecast
  10.3.3 Korea Market Amyotrophic Lateral Sclerosis (ALS) Treatment Forecast
  10.3.4 Southeast Asia Market Amyotrophic Lateral Sclerosis (ALS) Treatment Forecast
  10.3.5 India Market Amyotrophic Lateral Sclerosis (ALS) Treatment Forecast
  10.3.6 Australia Market Amyotrophic Lateral Sclerosis (ALS) Treatment Forecast
10.4 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Forecast by Country (2026-2031)
  10.4.1 Germany Market Amyotrophic Lateral Sclerosis (ALS) Treatment Forecast
  10.4.2 France Market Amyotrophic Lateral Sclerosis (ALS) Treatment Forecast
  10.4.3 UK Market Amyotrophic Lateral Sclerosis (ALS) Treatment Forecast
  10.4.4 Italy Market Amyotrophic Lateral Sclerosis (ALS) Treatment Forecast
  10.4.5 Russia Market Amyotrophic Lateral Sclerosis (ALS) Treatment Forecast
10.5 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Forecast by Region (2026-2031)
  10.5.1 Egypt Market Amyotrophic Lateral Sclerosis (ALS) Treatment Forecast
  10.5.2 South Africa Market Amyotrophic Lateral Sclerosis (ALS) Treatment Forecast
  10.5.3 Israel Market Amyotrophic Lateral Sclerosis (ALS) Treatment Forecast
  10.5.4 Turkey Market Amyotrophic Lateral Sclerosis (ALS) Treatment Forecast
10.6 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Forecast by Type (2026-2031)
10.7 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Forecast by Application (2026-2031)
  10.7.1 GCC Countries Market Amyotrophic Lateral Sclerosis (ALS) Treatment Forecast

11 KEY PLAYERS ANALYSIS

11.1 Mitsubishi Tanabe Pharma
  11.1.1 Mitsubishi Tanabe Pharma Company Information
  11.1.2 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Offered
  11.1.3 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2020-2025)
  11.1.4 Mitsubishi Tanabe Pharma Main Business Overview
  11.1.5 Mitsubishi Tanabe Pharma Latest Developments
11.2 Sanofi
  11.2.1 Sanofi Company Information
  11.2.2 Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Product Offered
  11.2.3 Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2020-2025)
  11.2.4 Sanofi Main Business Overview
  11.2.5 Sanofi Latest Developments
11.3 Mylan Pharma
  11.3.1 Mylan Pharma Company Information
  11.3.2 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Offered
  11.3.3 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2020-2025)
  11.3.4 Mylan Pharma Main Business Overview
  11.3.5 Mylan Pharma Latest Developments
11.4 Apotex
  11.4.1 Apotex Company Information
  11.4.2 Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Product Offered
  11.4.3 Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2020-2025)
  11.4.4 Apotex Main Business Overview
  11.4.5 Apotex Latest Developments
11.5 Glemark Generics
  11.5.1 Glemark Generics Company Information
  11.5.2 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Product Offered
  11.5.3 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2020-2025)
  11.5.4 Glemark Generics Main Business Overview
  11.5.5 Glemark Generics Latest Developments
11.6 Covis Pharma
  11.6.1 Covis Pharma Company Information
  11.6.2 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Offered
  11.6.3 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2020-2025)
  11.6.4 Covis Pharma Main Business Overview
  11.6.5 Covis Pharma Latest Developments
11.7 Sun Pharma
  11.7.1 Sun Pharma Company Information
  11.7.2 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Offered
  11.7.3 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2020-2025)
  11.7.4 Sun Pharma Main Business Overview
  11.7.5 Sun Pharma Latest Developments
11.8 Lunan Pharma
  11.8.1 Lunan Pharma Company Information
  11.8.2 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Offered
  11.8.3 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2020-2025)
  11.8.4 Lunan Pharma Main Business Overview
  11.8.5 Lunan Pharma Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION


LIST OFTABLES

Table 1. Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size CAGR by Region (2020 VS 2024 VS 2031) & ($ millions)
Table 2. Amyotrophic Lateral Sclerosis (ALS)Treatment Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Riluzole
Table 4. Major Players of Edaravone (Radicava)
Table 5. Major Players of Other
Table 6. Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size CAGR byType (2020 VS 2024 VS 2031) & ($ millions)
Table 7. Global Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size byType (2020-2025) & ($ millions)
Table 8. Global Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size Market Share byType (2020-2025)
Table 9. Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size CAGR by Application (2020 VS 2024 VS 2031) & ($ millions)
Table 10. Global Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size by Application (2020-2025) & ($ millions)
Table 11. Global Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size Market Share by Application (2020-2025)
Table 12. Global Amyotrophic Lateral Sclerosis (ALS)Treatment Revenue by Player (2020-2025) & ($ millions)
Table 13. Global Amyotrophic Lateral Sclerosis (ALS)Treatment Revenue Market Share by Player (2020-2025)
Table 14. Amyotrophic Lateral Sclerosis (ALS)Treatment Key Players Head office and Products Offered
Table 15. Amyotrophic Lateral Sclerosis (ALS)Treatment Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 16. New Products and Potential Entrants
Table 17. Mergers & Acquisitions, Expansion
Table 18. Global Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size by Region (2020-2025) & ($ millions)
Table 19. Global Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size Market Share by Region (2020-2025)
Table 20. Global Amyotrophic Lateral Sclerosis (ALS)Treatment Revenue by Country/Region (2020-2025) & ($ millions)
Table 21. Global Amyotrophic Lateral Sclerosis (ALS)Treatment Revenue Market Share by Country/Region (2020-2025)
Table 22. Americas Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size by Country (2020-2025) & ($ millions)
Table 23. Americas Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size Market Share by Country (2020-2025)
Table 24. Americas Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size byType (2020-2025) & ($ millions)
Table 25. Americas Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size Market Share byType (2020-2025)
Table 26. Americas Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size by Application (2020-2025) & ($ millions)
Table 27. Americas Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size Market Share by Application (2020-2025)
Table 28. APAC Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size by Region (2020-2025) & ($ millions)
Table 29. APAC Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size Market Share by Region (2020-2025)
Table 30. APAC Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size byType (2020-2025) & ($ millions)
Table 31. APAC Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size by Application (2020-2025) & ($ millions)
Table 32. Europe Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size by Country (2020-2025) & ($ millions)
Table 33. Europe Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size Market Share by Country (2020-2025)
Table 34. Europe Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size byType (2020-2025) & ($ millions)
Table 35. Europe Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size by Application (2020-2025) & ($ millions)
Table 36. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size by Region (2020-2025) & ($ millions)
Table 37. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size byType (2020-2025) & ($ millions)
Table 38. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size by Application (2020-2025) & ($ millions)
Table 39. Key Market Drivers & Growth Opportunities of Amyotrophic Lateral Sclerosis (ALS)Treatment
Table 40. Key Market Challenges & Risks of Amyotrophic Lateral Sclerosis (ALS)Treatment
Table 41. Key IndustryTrends of Amyotrophic Lateral Sclerosis (ALS)Treatment
Table 42. Global Amyotrophic Lateral Sclerosis (ALS)Treatment Market SizeForecast by Region (2026-2031) & ($ millions)
Table 43. Global Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size Market ShareForecast by Region (2026-2031)
Table 44. Global Amyotrophic Lateral Sclerosis (ALS)Treatment Market SizeForecast byType (2026-2031) & ($ millions)
Table 45. Global Amyotrophic Lateral Sclerosis (ALS)Treatment Market SizeForecast by Application (2026-2031) & ($ millions)
Table 46. MitsubishiTanabe Pharma Details, CompanyType, Amyotrophic Lateral Sclerosis (ALS)Treatment Area Served and Its Competitors
Table 47. MitsubishiTanabe Pharma Amyotrophic Lateral Sclerosis (ALS)Treatment Product Offered
Table 48. MitsubishiTanabe Pharma Amyotrophic Lateral Sclerosis (ALS)Treatment Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 49. MitsubishiTanabe Pharma Main Business
Table 50. MitsubishiTanabe Pharma Latest Developments
Table 51. Sanofi Details, CompanyType, Amyotrophic Lateral Sclerosis (ALS)Treatment Area Served and Its Competitors
Table 52. Sanofi Amyotrophic Lateral Sclerosis (ALS)Treatment Product Offered
Table 53. Sanofi Amyotrophic Lateral Sclerosis (ALS)Treatment Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 54. Sanofi Main Business
Table 55. Sanofi Latest Developments
Table 56. Mylan Pharma Details, CompanyType, Amyotrophic Lateral Sclerosis (ALS)Treatment Area Served and Its Competitors
Table 57. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS)Treatment Product Offered
Table 58. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS)Treatment Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 59. Mylan Pharma Main Business
Table 60. Mylan Pharma Latest Developments
Table 61. Apotex Details, CompanyType, Amyotrophic Lateral Sclerosis (ALS)Treatment Area Served and Its Competitors
Table 62. Apotex Amyotrophic Lateral Sclerosis (ALS)Treatment Product Offered
Table 63. Apotex Amyotrophic Lateral Sclerosis (ALS)Treatment Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 64. Apotex Main Business
Table 65. Apotex Latest Developments
Table 66. Glemark Generics Details, CompanyType, Amyotrophic Lateral Sclerosis (ALS)Treatment Area Served and Its Competitors
Table 67. Glemark Generics Amyotrophic Lateral Sclerosis (ALS)Treatment Product Offered
Table 68. Glemark Generics Amyotrophic Lateral Sclerosis (ALS)Treatment Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 69. Glemark Generics Main Business
Table 70. Glemark Generics Latest Developments
Table 71. Covis Pharma Details, CompanyType, Amyotrophic Lateral Sclerosis (ALS)Treatment Area Served and Its Competitors
Table 72. Covis Pharma Amyotrophic Lateral Sclerosis (ALS)Treatment Product Offered
Table 73. Covis Pharma Amyotrophic Lateral Sclerosis (ALS)Treatment Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 74. Covis Pharma Main Business
Table 75. Covis Pharma Latest Developments
Table 76. Sun Pharma Details, CompanyType, Amyotrophic Lateral Sclerosis (ALS)Treatment Area Served and Its Competitors
Table 77. Sun Pharma Amyotrophic Lateral Sclerosis (ALS)Treatment Product Offered
Table 78. Sun Pharma Amyotrophic Lateral Sclerosis (ALS)Treatment Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 79. Sun Pharma Main Business
Table 80. Sun Pharma Latest Developments
Table 81. Lunan Pharma Details, CompanyType, Amyotrophic Lateral Sclerosis (ALS)Treatment Area Served and Its Competitors
Table 82. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS)Treatment Product Offered
Table 83. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS)Treatment Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 84. Lunan Pharma Main Business
Table 85. Lunan Pharma Latest Developments



LIST OFFIGURES

Figure 1. Amyotrophic Lateral Sclerosis (ALS)Treatment Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size Growth Rate (2020-2031) ($ millions)
Figure 6. Amyotrophic Lateral Sclerosis (ALS)Treatment Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 7. Amyotrophic Lateral Sclerosis (ALS)Treatment Sales Market Share by Country/Region (2024)
Figure 8. Amyotrophic Lateral Sclerosis (ALS)Treatment Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 9. Global Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size Market Share byType in 2024
Figure 10. Amyotrophic Lateral Sclerosis (ALS)Treatment in Hospital
Figure 11. Global Amyotrophic Lateral Sclerosis (ALS)Treatment Market: Hospital (2020-2025) & ($ millions)
Figure 12. Amyotrophic Lateral Sclerosis (ALS)Treatment in Drugs Store
Figure 13. Global Amyotrophic Lateral Sclerosis (ALS)Treatment Market: Drugs Store (2020-2025) & ($ millions)
Figure 14. Amyotrophic Lateral Sclerosis (ALS)Treatment in Other
Figure 15. Global Amyotrophic Lateral Sclerosis (ALS)Treatment Market: Other (2020-2025) & ($ millions)
Figure 16. Global Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size Market Share by Application in 2024
Figure 17. Global Amyotrophic Lateral Sclerosis (ALS)Treatment Revenue Market Share by Player in 2024
Figure 18. Global Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size Market Share by Region (2020-2025)
Figure 19. Americas Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size 2020-2025 ($ millions)
Figure 20. APAC Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size 2020-2025 ($ millions)
Figure 21. Europe Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size 2020-2025 ($ millions)
Figure 22. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size 2020-2025 ($ millions)
Figure 23. Americas Amyotrophic Lateral Sclerosis (ALS)Treatment Value Market Share by Country in 2024
Figure 24. United States Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size Growth 2020-2025 ($ millions)
Figure 25. Canada Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size Growth 2020-2025 ($ millions)
Figure 26. Mexico Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size Growth 2020-2025 ($ millions)
Figure 27. Brazil Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size Growth 2020-2025 ($ millions)
Figure 28. APAC Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size Market Share by Region in 2024
Figure 29. APAC Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size Market Share byType (2020-2025)
Figure 30. APAC Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size Market Share by Application (2020-2025)
Figure 31. China Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size Growth 2020-2025 ($ millions)
Figure 32. Japan Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size Growth 2020-2025 ($ millions)
Figure 33. South Korea Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size Growth 2020-2025 ($ millions)
Figure 34. Southeast Asia Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size Growth 2020-2025 ($ millions)
Figure 35. India Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size Growth 2020-2025 ($ millions)
Figure 36. Australia Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size Growth 2020-2025 ($ millions)
Figure 37. Europe Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size Market Share by Country in 2024
Figure 38. Europe Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size Market Share byType (2020-2025)
Figure 39. Europe Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size Market Share by Application (2020-2025)
Figure 40. Germany Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size Growth 2020-2025 ($ millions)
Figure 41.France Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size Growth 2020-2025 ($ millions)
Figure 42. UK Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size Growth 2020-2025 ($ millions)
Figure 43. Italy Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size Growth 2020-2025 ($ millions)
Figure 44. Russia Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size Growth 2020-2025 ($ millions)
Figure 45. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size Market Share by Region (2020-2025)
Figure 46. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size Market Share byType (2020-2025)
Figure 47. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size Market Share by Application (2020-2025)
Figure 48. Egypt Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size Growth 2020-2025 ($ millions)
Figure 49. South Africa Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size Growth 2020-2025 ($ millions)
Figure 50. Israel Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size Growth 2020-2025 ($ millions)
Figure 51.Turkey Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size Growth 2020-2025 ($ millions)
Figure 52. GCC Countries Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size Growth 2020-2025 ($ millions)
Figure 53. Americas Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size 2026-2031 ($ millions)
Figure 54. APAC Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size 2026-2031 ($ millions)
Figure 55. Europe Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size 2026-2031 ($ millions)
Figure 56. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size 2026-2031 ($ millions)
Figure 57. United States Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size 2026-2031 ($ millions)
Figure 58. Canada Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size 2026-2031 ($ millions)
Figure 59. Mexico Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size 2026-2031 ($ millions)
Figure 60. Brazil Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size 2026-2031 ($ millions)
Figure 61. China Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size 2026-2031 ($ millions)
Figure 62. Japan Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size 2026-2031 ($ millions)
Figure 63. Korea Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size 2026-2031 ($ millions)
Figure 64. Southeast Asia Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size 2026-2031 ($ millions)
Figure 65. India Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size 2026-2031 ($ millions)
Figure 66. Australia Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size 2026-2031 ($ millions)
Figure 67. Germany Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size 2026-2031 ($ millions)
Figure 68.France Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size 2026-2031 ($ millions)
Figure 69. UK Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size 2026-2031 ($ millions)
Figure 70. Italy Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size 2026-2031 ($ millions)
Figure 71. Russia Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size 2026-2031 ($ millions)
Figure 72. Egypt Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size 2026-2031 ($ millions)
Figure 73. South Africa Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size 2026-2031 ($ millions)
Figure 74. Israel Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size 2026-2031 ($ millions)
Figure 75.Turkey Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size 2026-2031 ($ millions)
Figure 76. Global Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size Market ShareForecast byType (2026-2031)
Figure 77. Global Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size Market ShareForecast by Application (2026-2031)
Figure 78. GCC Countries Amyotrophic Lateral Sclerosis (ALS)Treatment Market Size 2026-2031 ($ millions)